Skip to content

G&A at other companies

LeMaitre Vascular logo
LeMaitre VascularLMAT
$12.05M+14.9%

Other financials

Income statement

See full
Revenue$27.5M+24.7%
Gross profit$17.5M+18.2%
Operating income$27.0K+105%
Net income$1.2M+365%
EPS (diluted)$0.02

Balance sheet

See full
Cash & equivalents$22.8M-65.9%
Total debt$17.4M-35.6%
Total equity$372.2M+5.6%
Total assets$400.9M+1.5%

Cash flow

See full
Operating cash flow-$491.0K-128%
CapEx$167.0K-4.6%
Free cash flow-$658.0K-142%

Valuation

See full
Market cap$1.25B+33.1%
Enterprise value$1.24B+38.1%
P/S12.5×+0.5×

Profitability

See full
Gross margin66.9%
Operating margin-16.7%
Net margin-68.7%
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0.0×
Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioLife Solutions's G&A?
BioLife Solutions (BLFS) reported G&A of $12.21M in Q1 2026.
How has BioLife Solutions's G&A changed year-over-year?
BioLife Solutions's G&A increased by 7.5% year-over-year, from $11.35M to $12.21M.
What is the long-term trend for BioLife Solutions's G&A?
Over 4 years (2021 to 2025), BioLife Solutions's G&A has grown at a 7.7% compound annual growth rate (CAGR), from $33.67M to $45.37M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.